肺动脉高压对心室辅助装置患者移植结局的影响
该研究基于美国器官共享网络(UNOS)2008至2015年成人心脏移植注册数据,比较持续流左心室辅助装置(LVAD)与非VAD患者在移植时不同肺血管阻力(PVR)水平与移植后生存的关系。结果显示无显著证据表明移植前PVR对移植后生存的影响在LVAD与非LVAD患者间存在差异,但极高PVR患者的移植候选资格仍需进一步研究。
要点
- LVAD与非LVAD队列中PVR升高均与死亡风险轻度增加相关。
- 高PVR的LVAD组生存最差但未达统计学显著,可能受样本量限制。
- 极高PVR患者即使植入LVAD后行心脏移植的候选资格仍待明确。
核心结论
- 基于UNOS数据库分析,无显著证据表明移植前PVR对移植后生存的影响在LVAD与非LVAD患者间更高。
- 需进一步研究明确极高PVR患者即使经LVAD支持后的心脏移植候选资格。
研究设计与样本
- 回顾性队列研究,使用美国器官共享网络(UNOS)注册数据,纳入2008至2015年接受心脏移植的成人。
- 非LVAD队列6270例(低PVR 4385例、中PVR 1643例、高PVR 242例),LVAD队列4111例(低PVR 3227例、中PVR 798例、高PVR 86例),按PVR<3、3至<6、≥6分组,用Cox回归计算校正风险比(aHR)。
主要发现
- 高PVR的LVAD组生存最差,但差异不显著(P = .300),可能与把握度低有关。
- 非LVAD队列死亡aHR为1.047(95%CI 1.010-1.088),LVAD队列为1.063(95%CI 1.010-1.119)。
- 立方样条分析显示PVR与aHR呈非线性关联,尤其在LVAD队列中。
临床怎么用
- 移植前评估PVR时,LVAD与非LVAD患者的移植后生存风险关联相似,不应仅凭LVAD状态区别对待PVR的影响。
- 对极高PVR患者即使已植入LVAD,心脏移植决策仍需个体化并进一步评估。
局限性
- 为回顾性注册数据库分析,存在混杂与选择偏倚可能。
- 高PVR亚组样本量小、把握度低,尤其LVAD高PVR组仅86例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although extremely high pulmonary vascular resistance (PVR) is a relative contraindication for heart transplantation (HTx), recent data with continuous-flow left ventricular assist devices (LVADs) indicate HTx outcomes may be different when high PVR is managed with an LVAD. This study clarifies the contemporary association between PVR at HTx and posttransplant survival in LVAD vs non-LVAD cohorts. METHODS: We reviewed the United Network for Organ Sharing registry for adults who received a transplant from 2008 to 2015. In those with continuous-flow LVADs and those with no VADs at HTx, (non-VAD), we grouped patients by low PVR (PVR <3), intermediate PVR (PVR 3 to <6), and high PVR (PVR ≥6) groups. Adjusted hazard ratios (aHRs) for death after HTx were calculated by Cox regression. RESULTS: The non-LVAD cohort included 6270 patients (4385 in low, 1643 in intermediate, and 242 in high PVR), and the LVAD cohort included 4111 patients (3227 in low, 798 in intermediate, and 86 in high PVR). The high PVR LVAD group had the worst survival, which was not significant, likely to low power (P = .300). The aHR for death in non-LVAD was 1.047 (95% confidence interval, 1.010-1.088) and in LVAD was 1.063 (95% confidence interval, 1.010-1.119). Cubic spline analysis demonstrated nonlinear associations between PVR and the aHR, especially in the LVAD cohort. CONCLUSIONS: There was no significant evidence to conclude the effect of pretransplant PVR on posttransplant survival is higher in LVAD vs non-LVAD patients, based on analysis of the United Network for Organ Sharing database. However, further investigations are indicated to clarify HTx candidacy in those with extremely high PVR even after LVAD.
引用
- Ando M, Takayama H, Kurlansky PA, et al. Effect of Pulmonary Hypertension on Transplant Outcomes in Patients With Ventricular Assist Devices. Ann Thorac Surg. 2019. PMID: 31770504. doi:10.1016/j.athoracsur.2019.09.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。